kushenol A: a tyrosinase inhibitor derived from Sophora flavescens [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44563121 |
| CHEMBL ID | 455679 |
| CHEBI ID | 197206 |
| Synonym |
|---|
| kushenol a |
| CHEMBL455679 |
| (2s)-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-[(2r)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one |
| CHEBI:197206 |
| bdbm50377945 |
| 99217-63-7 |
| AKOS032948966 |
| HY-N2278 |
| CS-0019607 |
| MS-27020 |
| DTXSID701318374 |
| kushenola |
| (2s)-2,3-dihydro-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-[(2r)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-4h-1-benzopyran-4-one |
| 4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-[(2r)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-, (2s)- |
| S7LW4HSS6R |
| 4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-[5-methyl-2-(1-methylethenyl)-4-hexenyl]-, [s-(r*,s*)]- |
| (-)-kushenol a |
| Class | Description |
|---|---|
| flavanones | Members of the class of flavans with a 3,4-dihydro-2-aryl-2H-1-benzopyran-4-one skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-secretase 1 | Homo sapiens (human) | IC50 (µMol) | 2.6000 | 0.0006 | 1.6194 | 10.0000 | AID344054 |
| Beta-secretase 1 | Homo sapiens (human) | Ki | 3.0000 | 0.0003 | 1.3524 | 8.0000 | AID344054 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| amyloid-beta binding | Beta-secretase 1 | Homo sapiens (human) |
| endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| aspartic-type endopeptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| protein binding | Beta-secretase 1 | Homo sapiens (human) |
| peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| beta-aspartyl-peptidase activity | Beta-secretase 1 | Homo sapiens (human) |
| enzyme binding | Beta-secretase 1 | Homo sapiens (human) |
| protein serine/threonine kinase binding | Beta-secretase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID344054 | Inhibition of human BACE1 | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| AID344052 | Inhibition of human BACE1 expressed in HEK293 cells assessed as reduction in soluble APPalpha level after 4 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| AID410031 | Inhibition of Clostridium perfringens neuraminidase | 2008 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23 | Pterocarpans and flavanones from Sophora flavescens displaying potent neuraminidase inhibition. |
| AID410032 | Inhibition of Clostridium perfringens neuraminidase by Lineweaver-Burke plot | 2008 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23 | Pterocarpans and flavanones from Sophora flavescens displaying potent neuraminidase inhibition. |
| AID344053 | Inhibition of human BACE1 expressed in HEK293 cells assessed as reduction in soluble APPbeta level after 4 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||